Premier Integrated Labs is leading efforts to advance early diagnosis and understanding of Alzheimer’s disease in Malaysia – a critical step in improving outcomes for patients and families affected by the condition.

On 22 April 2025, Premier Integrated Labs (PIL) launched a nationwide Continuing Medical Education tour in Penang, in collaboration with Mayo Clinic Laboratories and Eisai Co., Ltd.
The inaugural event brought together neurology specialists from both public and private hospitals to spotlight the importance of early detection and biomarker-based testing for Alzheimer’s.
Dr Jaron L from Mayo Clinic Laboratories highlighted the benefits of biomarker-driven diagnostics, while Dr Yew Keong Ng from Eisai shared insights into the evolving diagnostics landscape in Malaysia. The strong turnout underscored the clinical community’s shared commitment to tackling one of the most pressing neurological challenges of our time.
Separately, PIL also participated in a strategic session with YBhg Datuk Dr Muhammad Radzi Abu Hassan, former Director-General of Health, Malaysia Ministry of Health, to present updates on the ongoing study “Whole Exome Sequencing in Late-Onset Alzheimer’s Disease (LOAD) in Peninsular Malaysia.” The study seeks to uncover genomic markers and better understand the clinical characteristics of LOAD among local patients.
Representing PIL were CEO Hareeff Muhammed, Sayyidi Hamzi, and Dr Zubaidah, alongside collaborators Dr Hans Prakash (Institute for Medical Research) and Dr Cheah Wee Kooi (Hospital Taiping).
These initiatives reflect PIL’s dedication to fostering clinical collaboration, advancing diagnostics, and driving evidence-based care in the fight against Alzheimer’s disease.